207 related articles for article (PubMed ID: 30195927)
1. Using Smaller-Than-Standard Radiation Treatment Margins Does Not Change Survival Outcomes in Patients with High-Grade Gliomas.
Guram K; Smith M; Ginader T; Bodeker K; Pelland D; Pennington E; Buatti JM
Pract Radiat Oncol; 2019 Jan; 9(1):16-23. PubMed ID: 30195927
[TBL] [Abstract][Full Text] [Related]
2. Intensity-modulated radiotherapy (IMRT) in pediatric low-grade glioma.
Paulino AC; Mazloom A; Terashima K; Su J; Adesina AM; Okcu MF; Teh BS; Chintagumpala M
Cancer; 2013 Jul; 119(14):2654-9. PubMed ID: 23633429
[TBL] [Abstract][Full Text] [Related]
3. Fractionated stereotactic radiosurgery with volumetric modulated arc therapy (Rapid Arc) for reradiation in recurrent high grade gliomas.
Anand AK; Kumar P; Patir R; Vaishya S; Bansal AK; Chaudhoory AR; Punnakal AU; Malhotra H; Munjal RK
J Cancer Res Ther; 2014; 10(1):97-102. PubMed ID: 24762494
[TBL] [Abstract][Full Text] [Related]
4. Volumetric Response and Survival of Patients With Bulky IDH-Mutated Grade 3 Glioma Managed With FET-FDG-Guided Integrated Boost IMRT.
Mills D; Horsley P; Venkatasha V; Back M
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):343-352. PubMed ID: 38553362
[TBL] [Abstract][Full Text] [Related]
5. Diffusion tensor imaging: possible implications for radiotherapy treatment planning of patients with high-grade glioma.
Jena R; Price SJ; Baker C; Jefferies SJ; Pickard JD; Gillard JH; Burnet NG
Clin Oncol (R Coll Radiol); 2005 Dec; 17(8):581-90. PubMed ID: 16372482
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes and dose-volume histogram analysis of simultaneous integrated boost method for malignant gliomas using intensity-modulated radiotherapy.
Nakamatsu K; Suzuki M; Nishimura Y; Kanamori S; Koike R; Shibata T; Shintani N; Okumura M; Okajima K; Akai F
Int J Clin Oncol; 2008 Feb; 13(1):48-53. PubMed ID: 18307019
[TBL] [Abstract][Full Text] [Related]
7. Subventricular zone involvement at recurrence is a strong predictive factor of outcome following high grade glioma reirradiation.
Attal J; Chaltiel L; Lubrano V; Sol JC; Lanaspeze C; Vieillevigne L; Latorzeff I; Cohen-Jonathan Moyal E
J Neurooncol; 2018 Jan; 136(2):413-419. PubMed ID: 29273890
[TBL] [Abstract][Full Text] [Related]
8. Quantitative dynamic susceptibility contrast perfusion-weighted imaging-guided customized gamma knife re-irradiation of recurrent high-grade gliomas.
Wang B; Zhao P; Zhang Y; Ge M; Lan C; Li C; Pang Q; Xu S; Liu Y
J Neurooncol; 2018 Aug; 139(1):185-193. PubMed ID: 29696532
[TBL] [Abstract][Full Text] [Related]
9. Sequential proton boost after standard chemoradiation for high-grade glioma.
Adeberg S; Bernhardt D; Harrabi SB; Uhl M; Paul A; Bougatf N; Verma V; Unterberg A; Wick W; Haberer T; Combs SE; Herfarth K; Debus J; Rieken S
Radiother Oncol; 2017 Nov; 125(2):266-272. PubMed ID: 29050959
[TBL] [Abstract][Full Text] [Related]
10. Anisotropic Bladder Planning Target Volume in Bladder Radiation Therapy.
Adil K; Popovic M; Cury FL; Faria SL; Duclos M; Souhami L
Pract Radiat Oncol; 2019 Jan; 9(1):24-28. PubMed ID: 30096379
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients.
Ulyte A; Katsaros VK; Liouta E; Stranjalis G; Boskos C; Papanikolaou N; Usinskiene J; Bisdas S
Neuroradiology; 2016 Dec; 58(12):1197-1208. PubMed ID: 27796446
[TBL] [Abstract][Full Text] [Related]
12. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma.
McDonald MW; Shu HK; Curran WJ; Crocker IR
Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):130-6. PubMed ID: 20399036
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated Stereotactic Radiotherapy as a Salvage Therapy for Recurrent High-Grade Gliomas: Single-Center Experience.
Reynaud T; Bertaut A; Farah W; Thibouw D; Crehange G; Truc G; Vulquin N
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806498. PubMed ID: 30343637
[TBL] [Abstract][Full Text] [Related]
14. Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis.
Combs SE; Bruckner T; Mizoe JE; Kamada T; Tsujii H; Kieser M; Debus J
Radiother Oncol; 2013 Jul; 108(1):132-5. PubMed ID: 23932193
[TBL] [Abstract][Full Text] [Related]
15. Invasion is not an independent prognostic factor in high-grade glioma.
Narayana A; Perretta D; Kunnakkat S; Gruber D; Golfinos J; Parker E; Medabalmi P; Zagzag D; Pat Eagan RN; Gruber M
J Cancer Res Ther; 2011; 7(3):331-5. PubMed ID: 22044816
[TBL] [Abstract][Full Text] [Related]
16. Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition.
Straube C; Elpula G; Gempt J; Gerhardt J; Bette S; Zimmer C; Schmidt-Graf F; Meyer B; Combs SE
Strahlenther Onkol; 2017 Nov; 193(11):897-909. PubMed ID: 28616821
[TBL] [Abstract][Full Text] [Related]
17. Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial.
Ballo MT; Urman N; Lavy-Shahaf G; Grewal J; Bomzon Z; Toms S
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1106-1113. PubMed ID: 31026557
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
Ney DE; Carlson JA; Damek DM; Gaspar LE; Kavanagh BD; Kleinschmidt-DeMasters BK; Waziri AE; Lillehei KO; Reddy K; Chen C
J Neurooncol; 2015 Mar; 122(1):135-43. PubMed ID: 25524817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
